Abstract
Seventy percent of pharmaceutical companies expect their collaborations will primarily take the traditional forms of out-licensing products or technology. Whereas research alliances, in-licensing, and co-development are quite established and traditional collaboration approaches, many established pharmaceutical companies have long considered out-licensing a difficult task. The purpose of this chapter is to illustrate how out-licensing by pharmaceutical companies can contribute to an increase in research and development (R&D) efficiency. A case study of Novartis demonstrates how the out-licensing can be successfully adopted and managed. Successfully executed out-licensing programs provide pharmaceutical firms with several benefits such as additional revenue generation, cost- and resource effectiveness, and mitigation of R&D related risks.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
